colorectal cancer
Conditions
Interventions
2:fasting
1:control(normal diet)
3:shorten fasting
Sponsors
Shanghai Cancer Center, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. Evidence of an individual signed and dated informed consent (ICD) indicating that the patient was informed of all relevant aspects of the study prior to registration and dietary intervention; 3. Willing and able to follow dietary intervention protocols, scheduled visits, treatment plans, laboratory tests and other procedures; 4. Histologically confirmed colorectal cancer requires radical surgery; 5. The following laboratory numerical definitions indicate adequate bone marrow and organ function: ANC>=1.5x10^9/l; Platelet >=100x10^9/L; Hemoglobin >=9.0 g/dl; Calcium (corrected for serum albumin) was in the normal range; Potassium was in the normal range or corrected with supplements; Creatinine 3G/dl; Fasting blood glucose <=200 mg/dl; Total cholesterol <=300 mg/dl; Triglyceride <=300mg/dl.
Exclusion criteria
Exclusion criteria: 1. Systematic treatment of colorectal cancer has been carried out in advance; 2. At the same time, the diagnosis of malignant tumors other than colorectal cancer; 3. Body mass index (BMI) 25 kg / m2 (> 25 kg / m2) at the time of study registration. If the body mass index is less than 10% and the patient's BMI is > 22 kg / m2 in the past three months, intentional weight loss is allowed; 6. Severe heart, liver, lung and kidney coexist; 7. The current status of pregnancy or lactation, in which pregnancy is defined as the state from pregnancy to termination of pregnancy, which is positive by hCG laboratory test (> 5miu / ml); 8. Active HBV or HCV infection; 9. Severe infections within 4 weeks before the start of dietary intervention, including but not limited to hospitalization due to infection, bacteremia or severe pneumonia complications; 10. Active autoimmune diseases requiring systematic treatment (i.e. use of disease modifiers, corticosteroids or immunosuppressants); 11. The history of recently diagnosed hypothyroidism has not been stable with alternative therapy (e.g. thyroxine) and blood endocrine profile; 12. Diagnosis of type I or type II diabetes requires medication (including but not limited to insulin, insulin secretagogues, and metformin); 13. Severe impairment of gastrointestinal (GI) function or GI disease may alter the digestion and absorption of nutrients during the refeeding phase (e.g., active ulcerative disease of the stomach or intestine, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); 14. Known history of human immunodeficiency virus (HIV) infection; 15. Clinical significant heart disease and / or recent cardiac events, including: history of angina pectoris, coronary artery bypass grafting (CABG), symptomatic pericarditis or myocardial infarction within 12 months prior to the start of study treatment; history of congestive heart failure (NYHA III-IV); and documented cardiomyopathy. In the past 12 months, there was a history of arrhythmia (e.g., ventricular tachycardia, chronic atrial fibrillation), complete left bundle branch block, high degree atrioventricular block (such as double bundle branch block, mobitz type II atrioventricular block and third degree atrioventricular block), supraventricular, borderline arrhythmia or abnormal conduction. Uncontrolled hypertension defined by SBP >=160 mmHg and / or DBP >=100 mmHg, with or without antihypertensive drugs. Known left ventricular ejection fraction (LVEF) is reduced to less than 50%, as assessed by multi gated radionuclide scanning (MUGA) or echocardiography. There have been previous symptomatic hypotension leading to coma; 16. Baseline fasting blood glucose <=65 mg/dl; 17. Patients with ongoing systemic corticosteroid therapy, or who received systemic corticosteroid therapy 2 weeks prior to study registration, or who have not yet recovered from the side effects of such treatment. The following uses of corticosteroids are permitted: topical use (for example, rash), inhalation spray (for example, obstructive respiratory disease), eye drops; 18. Any serious medical or mental illness, in the investigator's assessment, makes the patient unfit to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute and relative changes of peripheral blood mononuclear cells (PBMCs);NLR score of perioperative immune function changes; | — |
Countries
China
Contacts
Public ContactMeilin Weng
Outcome results
None listed